AH: Heidelberg Pharma AG Announces Updated Guidance
Ladenburg, Germany, 18 June 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it has adjusted its guidance for the current fiscal year published on 25 March 2024.
The Heidelberg Pharma Group expects for the financial year 2024 sales and other income between EUR 9.0 million and EUR 12.0 million (previously: EUR 11.0 million to EUR 15.0 million). The reason for the lower sales is that expected sales are likely to be delayed due to developments at the license partners. Operating expenses will remain between EUR 36.0 million and EUR 40.0 million. Based on these adjustments, an operating result (EBIT) between EUR -25.5 million and EUR -29.5 million is expected (previously: EUR -23.5 million to EUR -27.5 million).
For 2024, Heidelberg Pharma anticipates cash requirements of EUR 18.0 million to EUR 22.0 million (previously: EUR 28.0 million to EUR 32.0 million). Monthly cash consumption is expected to range between EUR 1.5 million and EUR 1.8 million per month (previously: EUR 2.3 million and EUR 2.7 million). Based on the existing planning and available funds, the company's financing is secured until mid-2025.
Taking into account a further expected payment of USD 75.0 million from HealthCare Royalty, the company assumes that financing will be available until the end of 2026.
+++ End of the ad hoc announcement +++